GlassScriptPhysician profile
Burcin U Fraser
NPI 1548444078
$6,521.09
in general payments reported to CMS, 2019-2025
36 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $870 · 2021: $711 · 2022: $602 · 2023: $850 · 2024: $1,150 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,533 · Consulting Fee: $40.99 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,532.69 |
| Consulting Fee | $40.99 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,007.10 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $813.91 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $729.04 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $717.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $511.25 | 2020-2025 | Cuvitru, Takhzyro |
| Kaleo, INC. | $344.70 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $279.37 | 2019-2023 | |
| Genentech USA, INC. | $268.06 | 2019-2025 | Xolair |
| Grifols USA, LLC | $204.37 | 2021-2025 | Xembify |
| Optinose US, INC. | $184.32 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $135.79 | 2022-2025 | Orladeyo |
| Shire North American Group INC | $124.29 | 2019 | |
| Pharming Healthcare, INC. | $117.47 | 2019-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $114.63 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $109.50 | 2025 | Neffy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $106.14 | 2019 | |
| Csl Behring | $89.82 | 2019-2025 | Hizentra, Andembry |
| Lilly USA, LLC | $66.14 | 2025 | Ebglyss, Taltz |
| Phadia US INC. | $57.00 | 2023-2025 | Immunocap |
| Aimmune Therapeutics, INC. | $55.68 | 2022 | |
| Galderma Laboratories, L.P. | $46.91 | 2025 | Nemluvio |
| Horizon Therapeutics Plc | $46.07 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $43.91 | 2025 | Zoryve |
| Adma Biomanufacturing LLC | $40.99 | 2025 | |
| Alk-Abello, INC | $40.60 | 2019-2021 | |
| Aytu Biopharma, INC. | $37.11 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $30.90 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.42 | 2020-2021 | |
| Aerin Medical INC. | $29.06 | 2024 | |
| Leo Pharma INC. | $27.35 | 2023 | Adbry |
| Amgen INC. | $26.44 | 2024 | Tezspire |
| Covis Pharma Gmbh | $22.20 | 2019 | |
| Hikma Pharmaceuticals USA | $18.15 | 2024 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $16.41 | 2020 | |
| Eyevance Pharmaceuticals LLC | $14.66 | 2021 | |
| Bio Products Laboratory USA, INC. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Burcin Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.